“Si shkenc\u00ebtar, e di q\u00eb shkenca mund t\u00eb p\u00ebrparoj\u00eb vet\u00ebm n\u00ebse njer\u00ebzit pranojn\u00eb t\u00eb marrin pjes\u00eb n\u00eb programe si ky. Un\u00eb punoj n\u00eb inteligjenc\u00ebn artificiale dhe jam i hapur p\u00ebr t\u00eb provuar gj\u00ebra t\u00eb reja”, ky ishte mesazhi i 67-vje\u00e7arit britanik Januz Rush, pacienti i par\u00eb q\u00eb mori vaksin\u00ebn kund\u00ebr kancerit t\u00eb mushk\u00ebrive.<\/p>\n
\u201cShpresoj se vaksina do t\u00eb luftoj\u00eb qelizat e kancerit dhe trajtimi do t\u00eb jet\u00eb efektiv\u201d, shtoi 67-vje\u00e7ari q\u00eb jeton n\u00eb Lond\u00ebr.<\/p>\n
Mendimi se trajtimi mund t\u00eb shp\u00ebtoj\u00eb mij\u00ebra jet\u00eb dhe t\u00eb b\u00ebhet m\u00eb i njohur dhe i disponuesh\u00ebm n\u00eb t\u00eb ardhmen \u00ebsht\u00eb ajo q\u00eb e shtyn at\u00eb t\u00eb adoptoj\u00eb inovacionin shkencor. Pacienti n\u00eb Spitalin Universitar t\u00eb Londr\u00ebs mori vaksin\u00ebn, e cila \u00ebsht\u00eb krijuar p\u00ebr t\u00eb nxitur sistemin imunitar p\u00ebr t\u00eb njohur dhe luftuar qelizat e kancerit. \u00cbsht\u00eb hera e par\u00eb q\u00eb ky trajtim nga kompania gjermane e bioteknologjis\u00eb BioNTech testohet tek nj\u00eb pacient me kancer. Vaksina, e njohur si BNT116 nga BioNTech, \u00ebsht\u00eb projektuar p\u00ebr t\u00eb luftuar qelizat e kancerit duke parandaluar p\u00ebrs\u00ebritjen e tyre.<\/p>\n
Prova klinike e faz\u00ebs 1, studimi i par\u00eb i BNT116 te njer\u00ebzit, ka filluar n\u00eb 34 institucione k\u00ebrkimore n\u00eb shtat\u00eb vende: Mbret\u00ebria e Bashkuar, Shtetet e Bashkuara, Gjermania, Hungaria, Polonia, Spanja dhe Turqia<\/p>\n","protected":false},"excerpt":{"rendered":"
“Si shkenc\u00ebtar, e di q\u00eb shkenca mund t\u00eb p\u00ebrparoj\u00eb vet\u00ebm n\u00ebse njer\u00ebzit pranojn\u00eb t\u00eb marrin pjes\u00eb n\u00eb programe si ky. Un\u00eb punoj n\u00eb inteligjenc\u00ebn artificiale dhe jam i hapur p\u00ebr t\u00eb provuar gj\u00ebra t\u00eb reja”, ky ishte mesazhi i 67-vje\u00e7arit britanik Januz Rush, pacienti i par\u00eb q\u00eb mori vaksin\u00ebn kund\u00ebr kancerit t\u00eb mushk\u00ebrive. \u201cShpresoj se<\/p>\n","protected":false},"author":1,"featured_media":8023,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"class_list":{"0":"post-8022","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-lifestyle"},"_links":{"self":[{"href":"https:\/\/revistatrend.com\/index.php\/wp-json\/wp\/v2\/posts\/8022","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/revistatrend.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/revistatrend.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/revistatrend.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/revistatrend.com\/index.php\/wp-json\/wp\/v2\/comments?post=8022"}],"version-history":[{"count":1,"href":"https:\/\/revistatrend.com\/index.php\/wp-json\/wp\/v2\/posts\/8022\/revisions"}],"predecessor-version":[{"id":8024,"href":"https:\/\/revistatrend.com\/index.php\/wp-json\/wp\/v2\/posts\/8022\/revisions\/8024"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/revistatrend.com\/index.php\/wp-json\/wp\/v2\/media\/8023"}],"wp:attachment":[{"href":"https:\/\/revistatrend.com\/index.php\/wp-json\/wp\/v2\/media?parent=8022"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/revistatrend.com\/index.php\/wp-json\/wp\/v2\/categories?post=8022"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/revistatrend.com\/index.php\/wp-json\/wp\/v2\/tags?post=8022"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}